A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
Conditions
- Cancer-associated Thrombosis
- Esophageal Cancer
- Stomach Cancer
- Hepatocellular Carcinoma
- Pancreatic Cancer
- Duodenal Cancer
- Esophagogastric Junction Cancer
- Malignant Gastrointestinal Stromal Tumor
- Ampulla of Vater Cancer
- Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)
Interventions
- DRUG: Rivaroxaban
- DRUG: Dalteparin
- DRUG: apixaban
Sponsor
Asan Medical Center